Transplanted human multipotent stromal cells reduce acute tongue fibrosis in rats.
- Author(s): Vahabzadeh-Hagh, Andrew M
- Goel, Alexander N
- Frederick, John W
- Berke, Gerald S
- Long, Jennifer L
- et al.
Published Web Locationhttps://doi.org/10.1002/lio2.202
Background:Tongue fibrosis resulting from head and neck cancer, surgery, radiation, chemotherapy, or a combination thereof devastates one's quality of life. Therapeutic options are limited. Here we investigate human bone marrow-derived multipotent stromal cells (MSC) as a novel injectable treatment for post-injury tongue fibrosis. Methods:MSCs were grown in culture. Eighteen athymic rats underwent unilateral partial glossectomy. After two weeks for scar formation, a single injection was performed in the tongue scar. Three treatment groups were studied: low and high concentration MSC, and control media injection. Tongues were harvested for evaluation at three weeks post-treatment. Results:Dense fibrosis was achieved in control animals at five weeks. High concentration MSC reduced cross sectional scar burden (P = .007) and pathologic score for inflammation and fibrosis. Conclusion:This study establishes the feasibility of a novel rodent tongue fibrosis model, and begins to assess the utility of human MSCs to reduce scar burden. Level of Evidence:N/a.